MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

VIRIDIAN THERAPEUTICS INC

Closed

SectorHealthcare

13.47 -0.3

Overview

Share price change

24h

Current

Min

13.27

Max

13.66

Key metrics

By Trading Economics

Income

-3M

-80M

Sales

-14K

72K

EPS

-0.81

Profit margin

-110,729.167

Employees

143

EBITDA

-3.2M

-79M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+204.29% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

-97M

1.1B

Previous open

13.77

Previous close

13.47

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

VIRIDIAN THERAPEUTICS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 wrz 2024, 20:38 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

10 wrz 2024, 14:42 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

Peer Comparison

Price change

VIRIDIAN THERAPEUTICS INC Forecast

Price Target

By TipRanks

204.29% upside

12 Months Forecast

Average 41.11 USD  204.29%

High 50 USD

Low 27 USD

Based on 10 Wall Street analysts offering 12 month price targets forVIRIDIAN THERAPEUTICS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

13.15 / 13.76Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$